Related Experiment Videos
[Therapy of advanced prostatic cancer]
1Ludwig-Boltzmann-Forschungsstelle für Langzeittherapie und Rehabilitation im Wilhelminenspital.
Wiener Medizinische Wochenschrift (1946)
|April 30, 1988
Summary
Prostate cancer is a polyclonal tumor, meaning it has diverse cell clones. Treatment should combine hormone therapy and chemotherapy, with prostate-specific antigen monitoring for progression.
Area of Science:
- Oncology
- Cancer Biology
Context:
- Prostate cancer exhibits polyclonal heterogeneity.
- Hormone therapy is a primary treatment, with 70-75% initial response in untreated patients.
- A significant proportion (25-30%) of tumors display inherent androgen resistance.
Purpose:
- To analyze treatment strategies for advanced prostate cancer based on its polyclonal nature.
- To evaluate the efficacy of hormone therapy and chemotherapy in managing androgen-resistant clones.
- To highlight the role of prostate-specific antigen (PSA) in monitoring treatment response and disease progression.
Summary:
- Prostate cancer's polyclonal nature necessitates a combined therapeutic approach.
- Hormone therapy shows variable response, with a subset of tumors resistant to androgen.
- Antiandrogenic therapy can achieve response in 30-38% of hormone-refractory cases.
- Cytostatic chemotherapy is indicated for androgen-insensitive cell clones.
- The optimal chemotherapy regimen (mono- vs. polychemotherapy) requires further investigation.
- Integrated hormone and chemotherapy, guided by PSA monitoring, is proposed for advanced prostate cancer.
Impact:
- Informs the development of personalized treatment strategies for advanced prostate cancer.
- Emphasizes the need to address tumor heterogeneity in therapeutic decision-making.
- Establishes PSA as a critical biomarker for early detection of treatment failure and progression.